JP6895944B2 - 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン - Google Patents

組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン Download PDF

Info

Publication number
JP6895944B2
JP6895944B2 JP2018242562A JP2018242562A JP6895944B2 JP 6895944 B2 JP6895944 B2 JP 6895944B2 JP 2018242562 A JP2018242562 A JP 2018242562A JP 2018242562 A JP2018242562 A JP 2018242562A JP 6895944 B2 JP6895944 B2 JP 6895944B2
Authority
JP
Japan
Prior art keywords
rsv
mva
nucleotide sequence
antigenic determinant
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018242562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019068833A (ja
Inventor
ケミナイ・セドリック
シュタイガーヴァルト・ロビン
チャップリン・パウル
Original Assignee
バヴァリアン・ノルディック・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2015524681A external-priority patent/JP6523955B2/ja
Application filed by バヴァリアン・ノルディック・アクティーゼルスカブ filed Critical バヴァリアン・ノルディック・アクティーゼルスカブ
Publication of JP2019068833A publication Critical patent/JP2019068833A/ja
Priority to JP2021094027A priority Critical patent/JP7317896B2/ja
Application granted granted Critical
Publication of JP6895944B2 publication Critical patent/JP6895944B2/ja
Priority to JP2023116634A priority patent/JP2023139095A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018242562A 2012-08-01 2018-12-26 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン Active JP6895944B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021094027A JP7317896B2 (ja) 2012-08-01 2021-06-04 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
JP2023116634A JP2023139095A (ja) 2012-08-01 2023-07-18 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261678367P 2012-08-01 2012-08-01
US61/678,367 2012-08-01
EP12005594 2012-08-01
EP12005594.2 2012-08-01
JP2015524681A JP6523955B2 (ja) 2012-08-01 2013-03-15 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015524681A Division JP6523955B2 (ja) 2012-08-01 2013-03-15 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021094027A Division JP7317896B2 (ja) 2012-08-01 2021-06-04 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン

Publications (2)

Publication Number Publication Date
JP2019068833A JP2019068833A (ja) 2019-05-09
JP6895944B2 true JP6895944B2 (ja) 2021-06-30

Family

ID=66440168

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018242562A Active JP6895944B2 (ja) 2012-08-01 2018-12-26 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
JP2021094027A Active JP7317896B2 (ja) 2012-08-01 2021-06-04 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021094027A Active JP7317896B2 (ja) 2012-08-01 2021-06-04 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン

Country Status (8)

Country Link
JP (2) JP6895944B2 (uk)
DK (1) DK2879702T3 (uk)
ES (1) ES2767324T3 (uk)
HU (1) HUE047102T2 (uk)
LT (1) LT2879702T (uk)
PT (1) PT2879702T (uk)
UA (1) UA123385C2 (uk)
ZA (1) ZA201500606B (uk)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021137023A (ja) * 2012-08-01 2021-09-16 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008114149A2 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
CN102711818B (zh) * 2009-08-04 2014-09-24 美利坚合众国政府疾病控制和预防中心,健康和公共事业部 抗rsv免疫原和免疫方法
WO2012048817A2 (en) 2010-10-15 2012-04-19 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara influenza vaccine
WO2012085936A2 (en) * 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
CA3158572A1 (en) 2012-08-01 2014-02-06 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
HUE047102T2 (hu) 2012-08-01 2020-04-28 Bavarian Nordic As Rekombináns módosított Vaccinia vírus Ankara (MVA) respiratorikus szincíciális vírus (RSV) vakcina

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021137023A (ja) * 2012-08-01 2021-09-16 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
JP7317896B2 (ja) 2012-08-01 2023-07-31 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン

Also Published As

Publication number Publication date
PT2879702T (pt) 2020-02-04
JP7317896B2 (ja) 2023-07-31
JP2021137023A (ja) 2021-09-16
ZA201500606B (en) 2020-05-27
HUE047102T2 (hu) 2020-04-28
UA123385C2 (uk) 2021-03-31
DK2879702T3 (da) 2020-02-24
LT2879702T (lt) 2020-02-10
ES2767324T3 (es) 2020-06-17
JP2019068833A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US10946089B2 (en) Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
Antonis et al. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge
JP7317896B2 (ja) 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
CN117551677A (zh) 一种以5型腺病毒为载体的猴痘病毒特异性融合蛋白疫苗
US20110052627A1 (en) Recombinant modified vaccinia virus measles vaccine
US20230233670A1 (en) A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200203

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200813

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210608

R150 Certificate of patent or registration of utility model

Ref document number: 6895944

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150